通过使用mycophenolate mofetil成功治疗与类固醇不耐药免疫相关的肺炎:一个病例报告
Hiroaki Ota1, Daichi Fujimoto1, Yoshiki Negi1
1Department of Respiratory Medicine and Hematology Hyogo Medical University Nishinomiya Hyogo Japan.
与类固醇耐药性免疫相关的肺炎的治疗具有挑战性. 甲酸莫菲提尔 (MMF) 有效地管理了一个对类固醇无反应的患者,显示症状和成像改善.
科学领域:
- 免疫学 免疫学 免疫学
- 肺部病理学 肺部病理学
- 药理学 药理学是指药理学的学科.
背景情况:
- 类固醇耐药性免疫相关肺炎是一个重大的临床挑战.
- 这种情况存在有限的基于证据的治疗策略.
- 最佳的免疫抑制疗法仍然不清楚.
研究的目的:
- 报告成功治疗类固醇耐药性免疫相关肺炎的情况.
- 在这种情况下,评估mycophenolate mofetil (MMF) 的疗效.
主要方法:
- 一个病例研究,一个患有类固醇耐药性免疫相关肺炎的患者.
- 最初使用高剂量的类固醇治疗没有反应.
- 为了治疗,添加了mycophenolate mofetil (MMF) 进行治疗.
主要成果:
- 患者在MMF给药后,症状和成像显著改善.
- 紧缩MMF导致成像发现的恶化.
- 重新升级的MMF剂量导致更好的成像.
结论:
- 菌酸莫菲蒂尔 (MMF) 显示在治疗类固醇耐药性免疫相关肺炎方面具有潜在的疗效.
- 这个案例提供了关于货币市场基金管理及其在管理类似情况中的作用的见解.
更多相关视频
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
03:22Author Spotlight: Advancing Pathogen Detection and Disease Assessment in Real-Time Using M-ROSE
Published on: March 1, 2024
相关概念视频
Cystic Fibrosis: Management
Sinus disease and chronic...
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
COPD: Management Using Bronchodilators and Corticosteroids
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
